Antibody drug conjugates (ADCs) are a new class of biopharmaceuticals that use monoclonal antibodies to target tumor cells to deliver potent cytotoxic drugs. So far, a total of 15 ADC drugs have been ...
Demonstrating Robust Capabilities: Throughout the collaboration, all technology transfers and GMP manufacturing batches were achieved successfully in a single attempt, underscoring robust commercial ...
-- Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. -- Chime Biologics will ...
Collaboration will provide for unified development and manufacture of antibody drug conjugates. CMC Biologics, a clinical and commercial manufacturer of monoclonal antibodies and other therapeutic ...
SUZHOU, China, Nov. 21, 2025 /PRNewswire/ -- On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market ...
Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG ®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years. Demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback